Silica-Induced Immunotoxicity: Chronic and Aberrant Activation of Immune Cells

[1]  P. Sfikakis,et al.  The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases. , 2015, Seminars in arthritis and rheumatism.

[2]  Ying Chen,et al.  Silica exposure and altered regulation of autoimmunity , 2014, Environmental Health and Preventive Medicine.

[3]  T. Otsuki,et al.  Immunostimulation by Silica Particles and the Development of Autoimmune Dysregulation , 2014 .

[4]  Elizabeth E Ward,et al.  Silica: A lung carcinogen , 2014, CA: a cancer journal for clinicians.

[5]  P. Muranski,et al.  Essentials of Th17 cell commitment and plasticity. , 2013, Blood.

[6]  V. Uversky,et al.  Encyclopedia of Metalloproteins , 2013, Springer New York.

[7]  W. Fujimoto,et al.  Environmental factors producing autoimmune dysregulation--chronic activation of T cells caused by silica exposure. , 2012, Immunobiology.

[8]  W. Fujimoto,et al.  Immunological Effects of Silica and Related Dysregulation of Autoimmunity , 2011 .

[9]  Wan-Wan Lin,et al.  Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. , 2011, Biochemical pharmacology.

[10]  T. Otsuki,et al.  Dysregulation of autoimmunity caused by silica exposure: Fas-mediated apoptosis in T lymphocytes derived from silicosis patients , 2011 .

[11]  T. Otsuki,et al.  Dysregulation of the immune system caused by silica and asbestos , 2010, Journal of immunotoxicology.

[12]  S. Murakami,et al.  Reductive Alteration of the Regulatory Function of the CD4+CD25+ T Cell Fraction in Silicosis Patients , 2010, International journal of immunopathology and pharmacology.

[13]  Z. Jaffar,et al.  Natural Foxp3+ regulatory T cells inhibit Th2 polarization but are biased toward suppression of Th17‐driven lung inflammation , 2010, Journal of leukocyte biology.

[14]  S. Anderton,et al.  Translational Mini‐Review Series on Th17 Cells: CD4+ T helper cells: functional plasticity and differential sensitivity to regulatory T cell‐mediated regulation , 2010, Clinical and experimental immunology.

[15]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[16]  S. Murakami,et al.  Soluble Interleukin-2 Receptor as an Indicator of Immunological Disturbance Found in Silicosis Patients , 2009, International journal of immunopathology and pharmacology.

[17]  J. O’Shea,et al.  Th17 cells: a new fate for differentiating helper T cells , 2008, Immunologic research.

[18]  D Rees,et al.  Silica, silicosis and tuberculosis. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  Graham M Lord,et al.  The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease , 2007, Clinical and experimental immunology.

[20]  A. Šedivá,et al.  Exposure to silica and risk of ANCA-associated vasculitis. , 2006, American journal of industrial medicine.

[21]  C. la Vecchia,et al.  Occupational silica exposure and lung cancer risk: a review of epidemiological studies 1996-2005. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  H. Sakaguchi,et al.  Reduced Function of CD4+25+ Regulatory T Cell Fraction in Silicosis Patients , 2006, International journal of immunopathology and pharmacology.

[23]  W. Fujimoto,et al.  Detection, epitope‐mapping and function of anti‐Fas autoantibody in patients with silicosis , 2005, Immunology.

[24]  A. Witkowska.  On the Role of sIL-2R Measurements in Rheumatoid Arthritis and Cancers , 2005, Mediators of inflammation.

[25]  Ping Wu,et al.  Induction of CD69 antigen expression in peripheral blood mononuclear cells on exposure to silica, but not by asbestos/chrysotile-A. , 2005, Immunology letters.

[26]  Y. Isozaki,et al.  Anti‐Caspase‐8 Autoantibody Response in Silicosis Patients is Associated with HLA‐DRB1, DQB1 and DPB1 Alleles , 2005, Journal of occupational health.

[27]  Y. Takasaki,et al.  Soluble Fas molecule in the serum of patients with systemic lupus erythematosus , 1996, Journal of Clinical Immunology.

[28]  S. Murakami.  Soluble interleukin-2 receptor in cancer. , 2004, Frontiers in bioscience : a journal and virtual library.

[29]  Bindu Raju,et al.  Silica, Some Silicates, Coal Dust and Para-aramid Fibrils. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 68 , 1998, Cancer Causes and Control.

[30]  K. Mulloy.  Silica exposure and systemic vasculitis. , 2003, Environmental health perspectives.

[31]  S. Sakaguchi,et al.  Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease. , 2003, Current molecular medicine.

[32]  D. Green,et al.  Activation‐induced cell death in T cells , 2003, Immunological reviews.

[33]  E. Hess.  Environmental chemicals and autoimmune disease: cause and effect. , 2002, Toxicology.

[34]  Y. Isozaki,et al.  Intramolecular epitope spreading among anti‐caspase‐8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals , 2002, Clinical and experimental immunology.

[35]  H. Sakaguchi,et al.  Detection of anti-topoisomerase I autoantibody in patients with silicosis , 2002, Environmental health and preventive medicine.

[36]  S. Maher,et al.  Activation‐induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack , 2002, Immunology and cell biology.

[37]  Sayuri Yamazaki,et al.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.

[38]  H. Sakaguchi,et al.  Autoantibodies detectable in the sera of silicosis patients. The relationship between the anti-topoisomerase I antibody response and HLA-DQB1*0402 allele in Japanese silicosis patients. , 2001, The Science of the total environment.

[39]  A. Ueki,et al.  Antidesmoglein Autoantibodies in Silicosis Patients with No Bullous Diseases , 2001, Dermatology.

[40]  M. Finkelstein.  Silica, silicosis, and lung cancer: a risk assessment. , 2000, American journal of industrial medicine.

[41]  H. Sakaguchi,et al.  Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients. , 2000, Immunology letters.

[42]  D. D'cruz.  Autoimmune diseases associated with drugs, chemicals and environmental factors. , 2000, Toxicology letters.

[43]  Otsuki,et al.  Over‐expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients , 2000, Clinical and experimental immunology.

[44]  G. Cooper,et al.  Occupational exposure to crystalline silica and autoimmune disease. , 1999, Environmental health perspectives.

[45]  M. Mayes,et al.  Epidemiologic studies of environmental agents and systemic autoimmune diseases. , 1999, Environmental health perspectives.

[46]  Jian Ni,et al.  A Newly Identified Member of Tumor Necrosis Factor Receptor Superfamily (TR6) Suppresses LIGHT-mediated Apoptosis* , 1999, The Journal of Biological Chemistry.

[47]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[48]  U. Anderegg,et al.  Silica induced scleroderma--clinical and experimental aspects. , 1998, The Journal of rheumatology.

[49]  H. Sakaguchi,et al.  Soluble Fas mRNA is dominantly expressed in cases with silicosis , 1998, Immunology.

[50]  A. Frey,et al.  Administration of silica sensitizes lipopolysaccharide responsiveness of murine macrophages but inhibits T and B cell priming by inhibition of antigen presenting function. , 1998, Immunological investigations.

[51]  C. Kallenberg,et al.  Silicon exposure and vasculitis. , 1998, Current opinion in rheumatology.

[52]  Y. Isozaki,et al.  Elevated soluble Fas/APO‐1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours , 1997, Clinical and experimental immunology.

[53]  K. Okumura,et al.  Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. , 1997, Arthritis and rheumatism.

[54]  O. Janssen,et al.  Antigen-induced death of T-lymphocytes. , 1997, Frontiers in bioscience : a journal and virtual library.

[55]  T. Koike,et al.  Serum levels of soluble Fas/APO‐1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases , 1997, Clinical and experimental immunology.

[56]  P. D’Haese,et al.  ANCA-associated diseases and silica exposure , 1997, Clinical reviews in allergy & immunology.

[57]  K. Steenland,et al.  Silica exposure and autoimmune diseases. , 1995, American journal of industrial medicine.

[58]  B. Milleron,et al.  Silica‐associated Connective Tissue Disease: A Study of 24 Cases , 1995, Medicine.

[59]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[60]  J. Sánchez-Román,et al.  Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica. , 1993, Annals of the rheumatic diseases.

[61]  O. J. Stone.  Autoimmunity as a secondary phenomenon in scleroderma (and so-called human adjuvant disease). , 1991, Medical Hypotheses.

[62]  U. Haustein,et al.  Silica-induced scleroderma. , 1990, Journal of the American Academy of Dermatology.

[63]  T. Sugihara,et al.  Two human myeloma cell lines, amylase‐producing KMS‐12‐PE and amylase‐non‐producing KMS‐12‐BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32) , 1989, British journal of haematology.

[64]  R. A. McReynolds,et al.  Immunotoxicology of silica. , 1982, Critical reviews in toxicology.

[65]  S. Levine,et al.  Enhancement of allergic encephalomyelitis by particulate adjuvants inoculated long before antigen. , 1980, The American journal of pathology.

[66]  E J Morgan,et al.  Silicosis and tuberculosis. , 1979, Chest.

[67]  T. Medsger,et al.  The association of progressive systemic sclerosis (scleroderma) with coal miners' pneumoconiosis and other forms of silicosis. , 1967, Annals of internal medicine.

[68]  A. Caplan.  Rheumatoid Disease and Pneumoconiosis (Caplan's Syndrome) , 1959, Proceedings of the Royal Society of Medicine.

[69]  A. Caplan.  Certain Unusual Radiological Appearances in the Chest of Coal-miners Suffering from Rheumatoid Arthritis , 1953, Thorax.